While I also don't believe we get to see anything, the result of this check into safety should become known to us because the board should be stopping a trial that is showing both efficacy to the treatment arm and danger to the placebo arm, and declare it a success without risking any more lives. There is a very good likelihood of that occurring based on what we know of severe Covid patients and our own EIND experience. I would be very surprised, since NP has repeatedly stated that there are quite a few deaths in this trial, if they didn't stop it and allow those patients access to Leronlimab. Or just allow them to be treated with whatever else is available, enter a new trial, or whatever. But if they can calculate that Leronlimab is working while placebo patients are dying it does stand to reason it would happen. That's their whole job, to see that occurring and make a smart call. I'm just worried it won't actually happen because the interim analysis is so close. Why wouldn't they have taken a look a week or two weeks ago when NP was saying that there were quite a few deaths?